» Articles » PMID: 16681705

Common Complaints, Difficult Diagnosis: Multiple Myeloma

Overview
Specialty Nursing
Date 2006 May 10
PMID 16681705
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To review the presenting signs and symptoms of multiple myeloma, its pathophysiology, diagnostic evaluation, and treatment options.

Data Sources: A literature review of research articles and publications by oncology experts who specialize in multiple myeloma, supplemented by a case study.

Conclusions: Multiple myeloma is a cancer of the geriatric population, with the average age at diagnosis between 65 and 68 years. As the population of those over age 65 is predicted to double by the year 2050, the incidence of myeloma is expected to increase. Nurse practitioners (NPs) must become familiar with the signs, symptoms, and complications of myeloma for patients to be diagnosed and referred to specialists in a timely manner.

Implications For Practice: Patients with multiple myeloma often present with vague, common symptoms such as back pain, bony pain, fatigue, and anemia. These symptoms may be treated as separate medical conditions if NPs fail to include multiple myeloma in their differential diagnosis. If NPs are educated on this malignancy, they will have the expertise to look for other signs of the disease such as hypercalcemia, pathological fractures, osteopenia, or renal failure. Without early recognition of multiple myeloma and referrals to oncology specialists, patients are left with a delayed diagnosis and poor symptom control.

Citing Articles

A Complex Presentation of Multiple Myeloma With Renal Complications in a Young Female: Diagnostic Challenges and Treatment Approach.

Prajapati H, Patel Y, Parmar A, Patel S, Shaikhjiwala T EJHaem. 2025; 6(1):e1093.

PMID: 39866922 PMC: 11760197. DOI: 10.1002/jha2.1093.


Optimal cut-off values and diagnostic significance of clinical laboratory indicators in newly diagnosed multiple myeloma.

Li M, Wu H, Shou C, Peng Y, Song X, Ying W Discov Oncol. 2024; 15(1):477.

PMID: 39331239 PMC: 11436520. DOI: 10.1007/s12672-024-01254-z.


Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.

Popat R, Lonial S, Voorhees P, Esposti S, Gorsh B, Gupta I J Adv Pract Oncol. 2023; 14(6):503-518.

PMID: 37808071 PMC: 10558016. DOI: 10.6004/jadpro.2023.14.6.4.


Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution.

Andriandi , Kamal A Ann Med Surg (Lond). 2019; 41:11-15.

PMID: 31011418 PMC: 6460220. DOI: 10.1016/j.amsu.2019.03.011.


The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period.

Oberoi D, White V, Seymour J, Prince H, Harrison S, Jefford M J Cancer Surviv. 2017; 11(3):329-338.

PMID: 28144891 DOI: 10.1007/s11764-016-0591-y.